NCT06852274View on ClinicalTrials.gov

Clostridium Butyricum CBM588® vs. Rifaximin for Symptomatic Uncomplicated Diverticular Disease (SUDD): A Real-World Retrospective Study

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

October 31, 2024

Conditions
Diverticular DiseasesGastro-Intestinal Disorder
Interventions
DIETARY_SUPPLEMENT

Clostridium butyricum CBM588® (Butirrisan®)

Probiotic

DRUG

Rifaximin 400 mg Oral Tablet

Antibiotic

Trial Locations (1)

Unknown

Medicine & Technological Innovation Dept. University of Insubria, Varese

All Listed Sponsors
collaborator

San Giovanni Addolorata Hospital

OTHER

lead

Dr. Amjad Khan

OTHER